-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Abivax Reveals Obefazimod's First Anti-Fibrotic Data In Preclinical Models Alongside Rapid Week 1 Symptomatic Response And Safety Analyses At ECCO 2026

Benzinga·02/23/2026 06:55:42
Listen to the news
  • 22 abstracts presented at European Crohn's and Colitis Organization's (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod's potential in inflammatory bowel disease
  • Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn's disease
  • A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of serious treatment emergent adverse events and study discontinuation similar to placebo
  • Symptomatic response of obefazimod was observed as early as week 1 (first time point evaluated) with symptomatic remission observed at week 2 (nominally significant p-value <0.05) in a pooled analysis of ABTECT-1 and ABTECT-2
  • Biomarker data from ABTECT-1 and ABTECT-2 induction trials indicate upregulation of miR-124 and reduction of key inflammatory cytokines (IL-17A and IL-6) toward homeostatic levels